A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent squamous NSCLC

Trial Profile

A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent squamous NSCLC

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
    • 15 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
    • 09 Sep 2015 Pooled analysis results of this and other phase II (JapicCTI-No.132073) trial presented at the 16th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top